Clinical trials: Unknown Primary Cancer
Neoplasms, Unknown Primary
Cost-effectiveness Study of miRview™ Mets in Patients With Cancer of Unknown Primary (CUP)
The aim of the study is in cancer of unknown primary (CUP) patients, to compare the cost-effectiveness of miRview™ mets test with conventional work-up in identifying the primary tumor site.
- Trial name
- NCT01202786
- Where
- 3 sites in Israel
- Volunteers
- 60 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Cancer of Unknown Primary Site
A Phase II/III Study of F520 Combined With Paclitaxel Plus Carboplatin in the Treatment of Cancer of Unknown Primary (CUP)
The purpose of this study is to evaluate the efficacy and safety of F520 combined with paclitaxel plus carboplatin as first-line treatment for cancer of unknown primary.This study consists of two parts, with a total planned…
- Trial name
- NCT07761429
- Testing
- F520 combined with chemotherapy
- Where
- China
- Volunteers
- 402 people
- Sponsor
- Shandong New Time Pharmaceutical Co., LTD
Stage III Breast Cancer, Stage IV Breast Cancer
Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs
The primary objective of this study, sponsored by Travera in Massachusetts, is to validate whether the mass response biomarker has potential to predict response of patients to specific therapies or therapeutic combinations using…
- Conditions
- Stage III Breast Cancer, Stage IV Breast Cancer, Stage III Lung Cancer, Stage IV Lung Cancer
- Trial name
- NCT04985357
- Sponsor
- Travera Inc